Loading...
•
Mar 31, 2022
Teva Q1 2022 Earnings Report
Teva's financial performance decreased due to lower revenues in North America and impacted by legal settlements and loss contingencies.
Key Takeaways
Teva reported a decrease in revenues and a GAAP diluted loss per share, mainly due to lower revenues in North America and legal settlements. However, it saw gains in market share for AJOVY in the United States and Europe and reaffirmed its earnings and cash flow guidance.
Revenues decreased by 8% to $3.7 billion compared to Q1 2021.
GAAP diluted loss per share was $0.86.
Non-GAAP diluted EPS was $0.55.
Free cash flow was $117 million.
Teva
Teva
Teva Revenue by Segment
Teva Revenue by Geographic Location
Revenue by Segment
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Markets Revenue
CapyFin.comOther Activities Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Markets Revenue
CapyFin.com Forward Guidance
Teva revised its 2022 revenue outlook lower due to foreign exchange fluctuations and increased competition for COPAXONE, while reaffirming its earnings and cash flow guidance.
Positive Outlook
- Revenues of $15.4 - $16.0 billion
- Adjusted EBITDA of $4.7 - $5.0 billion
- Non-GAAP diluted EPS of $2.40 - $2.60
- Free cash flow of $1.9 - $2.2 billion
- Non-GAAP Tax Rate 18% - 19%
Challenges Ahead
- Revenues outlook revised lower due to ongoing impact of foreign exchange fluctuations.
- COPAXONE revenues of approximately $750 million vs. previous outlook of approximately $850 million
- COPAXONE outlook revised lower mainly to reflect increased competition and foreign exchange fluctuations.
- Share Count 1,114 million shares
- CAPEX 0.6
Revenue & Expenses
Visualization of income flow from segment revenue to net income